How Hong Kong can lead in longevity medicine as silver economy grows

A profound demographic and economic shift is sweeping through Asia, quietly rewriting the rules of national development. The traditional paradigm of treating population ageing as a passive fiscal burden is being dismantled as Beijing makes the “silver economy” and proactive ageing strategies the pillars of national security and economic growth. China’s population aged 60 and above reached 320 million last year, accounting for 23 per cent of its citizenry. This is projected to climb to 400 million by 2035, or around 30 per cent of the population. The silver economy, valued at 7 trillion yuan (US$1.03 trillion), is expected to balloon to 30 trillion yuan, or 10 per cent of gross domestic product by 2035. This economic metamorphosis is not merely about building better elderly care infrastructure – it is the birth of longevity medicine. This emerging field focuses on extending people’s health span – the number of years a person lives an active life, free from chronic illness. Longevity medicine may sound like science fiction but is grounded in clinical science. Rather than wait for a patient to suffer a stroke or develop diabetes, doctors use advanced biological screening tools to analyse DNA modifications and determine a person’s biological age as opposed to their chronological age. Interventions include targeted cell-rejuvenation therapies that flush out “zombie cells” or compound molecules that repair DNA shielding to slow down cellular decay. The commercial appetite for these therapies is massive. Globally, the longevity market is valued at US$27.6 billion and projected to surpass US$67 billion by 2035. Growth is fastest in the Asia-Pacific region, with the market set to increase by 11.25 per cent annually. For Hong Kong, this is a strategic imperative – it must position itself as the premier regional hub for longevity research, clinical trials, regulatory approval and capital scaling. The city possesses an enviable and unique foundation. Southeast Asian medical tourists have long recognised Hong Kong’s clinical standards as among the highest in the world. This reputational capital is now paired with a rapidly evolving, business-friendly regulatory environment. Its innovative 1+ drug registration mechanism, launched in late 2023 and expanded across all new drugs in 2024, has drastically streamlined the approval process for breakthrough pharmaceuticals. Crucially, the Centre for Medical Products Regulation (CMPR), to be established this year, will transform the city’s capabilities. Instead of passive reliance on foreign watchdogs, Hong Kong, through the CMPR, will be able to assess chemical and biological therapeutics based on its own clinical trial data. This statutory framework, which will also encompass advanced medical devices, is designed to align with international standards. For the first time, securing regulatory approval in Hong Kong will grant a product regional credibility, offering an accelerated gateway into both mainland China and broader Asia-Pacific markets. However, a yawning gap exists between Hong Kong’s regulatory ambitions and institutional reality. Longevity medicine is structurally distinct from traditional geriatrics. Curating official support from Hong Kong’s gatekeeper institutions – namely the Health Bureau, Medical Council and Academy of Medicine – remains incredibly difficult. These statutory bodies are bound by traditional, deeply entrenched risk-reward frameworks. Historically tasked with regulating conventional, reactive medicine and legacy treatments, they are sceptical about advanced anti-ageing therapies and biological ageing markers. Longevity medicine lacks a formalised academic framework in Hong Kong and there is no structured ecosystem to train clinical specialists or recognise biological age reduction as a legitimate medical endpoint. Without a paradigm shift, the city risks strangling its newest industry while regional peers sprint ahead. Singapore has integrated longevity sciences into its national healthcare architecture and now has a dedicated clinical research centre at the National University of Singapore. Malaysia is rapidly capturing the premium medical tourism sector by packaging advanced stem cell therapies and regenerative wellness packages into highly competitive commercial portfolios. If Hong Kong remains hesitant, it will be permanently left behind. To bridge these gaps, Hong Kong must seize opportunities across academia, research and corporate commercialisation. The Hong Kong University of Science and Technology’s new medical school provides the perfect blank canvas. It should establish dedicated chairs and research positions in health span and longevity medicine. This would seed the market with clinical talent native to the discipline. Hong Kong must utilise its technology parks to form a cohesive ecosystem. Start-ups specialising in artificial-intelligence-driven drug discovery, cellular reprogramming and biological age testing can use these zones to run trials that bridge mainland and global markets. Ultimately, Hong Kong’s unique position offers advantages no other Asian city can match. It can act as the region’s research lead, leveraging its world-class universities; its drug lead, accelerated by the CMPR framework; and its medical services lead, drawing on its premium clinical reputation. Furthermore, as an international financial centre, Hong Kong remains the pre-eminent venue for biotechnology listings and venture capital scaling. China and Southeast Asia are experiencing an exponential growth in consumer demand for longevity products, from advanced cellular health supplements to novel regenerative stem cell treatments. Hong Kong has the infrastructure to validate these novel interventions safely, ethically and scientifically. By aligning its local economic restructuring with Beijing’s 15th five-year plan, Hong Kong can transform the challenge of an ageing population into a high-value industry. It is time for our medical establishment to look past traditional horizons and secure the city’s place at the vanguard of human health span extension.

How Hong Kong can lead in longevity medicine as silver economy grows

.css-1c6uqr6{color:inherit;font-weight:inherit;font-size:inherit;font-family:inherit;line-height:inherit;overflow-wrap:break-word;}City has unique conditions to be the premier regional hub for longevity research, clinical trials, regulatory approval and capital scaling

City has unique conditions to be the premier regional hub for longevity research, clinical trials, regulatory approval and capital scaling